Hoerr, Ingmar

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

Alberer, M., Gnad-Vogt, U., Hong, H. S., Mehr, K. T., Backert, L., Finak, G., Gottardo, R., Bica, M. A., Garofano, A., Koch, S. D., et al. (2017) · The Lancet

Rabies epidemiology and controlSARS-CoV-2 and COVID-19 Research

Cited by 530

Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients

Weide, B., Pascolo, S., Scheel, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T. K., Pawelec, G., Hoerr, I., Rammensee, H.-G., & Garbe, C. (2009) · Journal of Immunotherapy

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 378

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

Kübler, H., Scheel, B., Gnad-Vogt, U., Miller, K., Schultze-Seemann, W., vom Dorp, F., Parmiani, G., Hampel, C., Wedel, S., Trojan, L., et al. (2015) · Journal for Immunotherapy of Cancer

Immunotherapy and Immune ResponsesProstate Cancer Treatment and Research

Cited by 287

Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA

Weide, B., Carralot, J.-P., Reese, A., Scheel, B., Eigentler, T. K., Hoerr, I., Rammensee, H.-G., Garbe, C., & Pascolo, S. (2008) · Journal of Immunotherapy

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 261

Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients

Rittig, S. M., Haentschel, M., Weimer, K. J., Heine, A., Muller, M. R., Brugger, W., Horger, M. S., Maksimovic, O., Stenzl, A., Hoerr, I., et al. (2011) · Molecular Therapy

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 226

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

Sebastian, M., Schröder, A., Scheel, B., Hong, H. S., Muth, A., von Boehmer, L., Zippelius, A., Mayer, F., Reck, M., Atanackovic, D., et al. (2019) · Cancer Immunology, Immunotherapy

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 209

Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent

Probst, J., Weide, B., Scheel, B., Pichler, B. J., Hoerr, I., Rammensee, H.-G., & Pascolo, S. (2007) · Gene Therapy

RNA Interference and Gene DeliveryRNA and protein synthesis mechanisms

Cited by 206

Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines

Carralot, J.-P., Probst, J., Hoerr, I., Scheel, B., Teufel, R., Jung, G., Rammensee, H.-G., & Pascolo, S. (2004) · Cellular and Molecular Life Sciences CMLS

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 149

Characterization of the ribonuclease activity on the skin surface

Probst, J., Brechtel, S., Scheel, B., Hoerr, I., Jung, G., Rammensee, H.-G., & Pascolo, S. (2006) · Genetic Vaccines and Therapy

RNA Interference and Gene DeliveryRNA Research and Splicing

Cited by 84

Human peripheral blood monuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T-lymphocytes in vitro

Teufel, R., Carralot, J.-P., Scheel, B., Probst, J., Walter, S., Jung, G., Hoerr, I., Rammensee, H.-G., & Pascolo, S. (2005) · Cellular and Molecular Life Sciences

Immunotherapy and Immune ResponsesT-cell and B-cell Immunology

Cited by 22